| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J. Biol. Chem., Vol. 280, Issue 8, 6276-6284, February 25, 2005
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
¶¶¶
From the
Molecular Genetics, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02118, the Department of Human Genetics, Leiden University Medical Center, 2333AL Leiden, The Netherlands, the ¶Department of General Internal Medicine, Leiden University Medical Center, 2333AL, Leiden, The Netherlands, the ||TNO-Preventie en Gezondheid Prevention and Health, Gaubius Laboratory, Leiden 2333CK, The Netherlands, the **Department of Cardiology, Leiden University Medical Center, 2333AL, Leiden, The Netherlands, and the Department of Biochemistry, Institute of Molecular Biology and Biotechnology, University of Crete Medical School, Heraklion, Crete 71110 Greece
Received for publication, November 30, 2004
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
A series of recent studies used adenoviruses expressing full-length and truncated genomic apoE sequences to correct the high cholesterol profile of the apoE-deficient (apoE–/–) mice. It was shown that overexpression of full-length apoE (by infection of mice with 1–2 x 109 pfu) did not correct the high cholesterol levels of the apoE–/– mice, in contrast, it increased VLDL triglyceride secretion and induced hypertriglyceridemia (12–16). Overexpression of apoE3 or apoE4 also aggravated the hypercholesterolemia in apoE2 knock-in mice (17). However the high cholesterol profile of apoE–/– mice or the apoE2 knock-in mice was corrected by infection with truncated apoE forms lacking different segments of the carboxyl-terminal domain (12–17). The hypertriglyceridemia induced by full-length apoE was independent of the apoE phenotype and mouse strain and could be corrected by overexpression of lipoprotein lipase (15). In normal C57BL6 mice overexpression of full-length apoE induced combined hyperlipidemia characterized by high cholesterol and high triglycerides levels, whereas truncated apoE forms did not change the plasma lipid and lipoprotein levels of these mice (13). Finally, truncated apoE forms could not correct the high cholesterol profiles of the apoE–/– x LDLr–/– double-deficient mice but did not induce hypertriglyceridemia, indicating that the carboxyl-terminal region of apoE is responsible for the hypertriglyceridemia (15, 16). Use of a series of apoE deletion mutants extending from amino acid 1 to amino acids 185, 202, 229, or 259 mapped the region responsible for the hypertriglyceridemia between amino acids 260 and 299 of apoE (12–17). This region contains two hydrophobic stretches of amino acids between residues 261–269 and 276–283.
In the present study, the hydrophobic residues of both regions were mutated to alanines and the functions of the mutant apoE forms were studied in vivo using adenovirus-mediated gene transfer. This analysis showed that residues Leu-261, Trp-264, Phe-265, Leu-268, and Ala-269 can account for the apoE-induced hypertriglyceridemia. Furthermore, the 261–269 apoE sequence is responsible for displacing apoA-I from the HDL region, leading to reduction in plasma apoA-I and HDL levels.
|
EXPERIMENTAL PROCEDURES |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
The recombinant adenoviruses were constructed as described (14) using the Ad-Easy-1 system where the adenovirus construct is generated in bacteria BJ-5183 cells (18). Correct clones were propagated in RecA DH5
cells. The recombinant adenoviral vectors were linearized with PacI and used to infect 911 cells (19). Following large scale infection of human embryonic kidney 293 cell cultures, the recombinant adenoviruses were purified by two consecutive CsCl ultracentrifugation steps, dialyzed, and titrated (14). Usually, titers of 
2–5 x 1010 pfu/ml were obtained.
Cell Culture Studies—Human HTB13 cells (SW1783, human astrocytoma) grown to confluence in medium containing 10% fetal calf serum were infected with AdGFP-E4 or the adenoviruses expressing the mutant apoE forms AdGFP-E4-mut1 and AdGFP-E4-mut2 at a multiplicity of infection of 5. Twenty-four-hours postinfection, cell were washed twice with phosphate-buffered saline, and fresh serum-free medium was added. After 24 h of incubation, medium was collected and analyzed by enzyme-linked immunosorbent assay (ELISA) and SDS-PAGE for apoE expression.
Animal Studies—Female apoE-deficient mice 4–6-weeks-old were used in these studies. Groups of 8–10 female mice were injected intravenously through the tail vein with a dose of 2 x 109 pfu. Blood was obtained from the tail vein after a 4-h fast preceding adenoviral injection and 2, 3, 4, 5, and 6 days postinfection. Aliquots of plasma were stored at 4 and –20 °C.
RNA Analysis—To assess the expression of apoE4, apoE4-mut1, and apoE4-mut2 in infected mice, at least 3 mice from each group were sacrificed at 5 days postinfection. Livers were collected from individual animals, frozen in liquid nitrogen, and stored at –80 °C. Total RNA was isolated from the livers and analyzed for apoE mRNA expression by Northern blotting and quantitated by phosphorimaging (13).
FPLC Analysis and Lipid Determination—For FPLC analysis of serum samples, 12 µl of serum were diluted 1:5 with phosphate-buffered saline, and loaded onto a Superose 6 column in a SMART micro FPLC system (Amersham Biosciences), and eluted with phosphate-buffered saline. A total of 25 fractions of 50-µl volume each were collected for further analysis. Triglycerides and cholesterol were determined using the GPO-Trinder Kit (Sigma) and CHOL-MPR3 kit (Roche Applied Science), according to the manufacturer's instructions. The triglyceride and cholesterol concentrations of the serum and the FPLC fractions were determined spectrophotometrically at 540 and 492 nm, respectively, as described previously (14).
Quantification of Human ApoE—Human apoE concentrations were measured using sandwich ELISA (12–15).
Rate of VLDL Triglyceride Production in C57/BL6 Mice Infected with Different ApoE Forms—VLDL triglyceride secretion was determined following infection of C57BL6 mice with 2 x 109 pfu of adenoviruses expressing either WT apoE4, apoE4-mut1, or the control AdGFP adenovirus. Four days postinfection, mice were fasted for 4 h and then injected with Triton WR-1339 at a dose of 500 mg/kg of body weight, using a 15% solution (w/v) in 0.9% NaCl (Triton WR-1339 has been shown to completely inhibit VLDL catabolism (20)). Serum samples were isolated 20, 40, 60, and 90 min after injection with Triton WR-1339. Serum triglycerides were measured, and the rate of VLDL-triglyceride secretion expressed in mg/dl/min was determined as described (14).
Statistical Analysis—Comparison of data from two groups of mice were performed using the Student's t test.
Density Gradient Ultracentrifugation—To assess the ability of WT and mutant apoE forms to associate with different lipoproteins, 0.3 ml of serum from mice infected either with the control adenovirus AdGFP or adenoviruses expressing the WT apoE4, apoE4-mut1, or apoE4-mut2 were brought to a volume of 0.5 ml with phosphate-buffered saline and adjusted to a density of 1.23 g/ml with KBr. This solution was then overlaid with 1 ml of 1.21 g/ml KBr, 2.5 ml of 1.063 g/ml KBr, 0.5 of 1.019 g/ml KBr, and 0.5 ml of saline. The mixture was centrifuged for 22 h in a SW-41 rotor at 30,000 rpm. Following ultracentrifugation, 10 fractions of 0.5 ml were collected and analyzed by SDS-PAGE.
Electron Microscopy—Aliquots of the fractions from equilibrium density gradient centrifugation after dialysis against ammonium acetate and carbonate buffer were stained with sodium phosphotungstate, visualized in the Phillips CM-120 electron microscopy (Phillips Electron Optics, Eindhoven, Netherlands), and photographed as described previously (11). The photomicrographs were taken at x75,000 magnification and enlarged three times.
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
|
|
|
|
|
|
125 mg/dl in mice infected with the apoE4-expressing adenovirus, 2–6 days postinfection, to an average value of 10 mg/dl in mice infected with apoE4- and lipoprotein lipase-expressing adenoviruses (Fig. 6C). The lipoprotein lipase treatment reduced apoE levels from an average value of 150 mg/dl in mice treated with apoE4-mut2 alone to an average value of 40 mg/dl in mice treated with apoE4-mut2 and lipoprotein lipase (Fig. 6I). It is interesting that the greatest levels of apoE on days 2 and 3 postinfection with the apoE4-mut2-expressing adenovirus are associated with mild hypertriglyceridemia (Fig. 6, H and I). In contrast, the apoE levels of apoE4-mut1 remained high (average value of 170 mg/dl) with or without treatment with the LpL-expressing adenovirus (Fig. 6F). ApoE4 and ApoE4-mut2, but Not ApoE4-mut1, Displace ApoA-I from the HDL Region and Promote Formation of Discoidal HDL Particles—To establish the ability of apoE4, apoE4-mut1, and apoE4-mut2 to associate with different lipoproteins, 300 µl of serum from mice infected with either recombinant adenoviruses expressing apoE4, apoE4-mut1, or apoE4-mut2 were fractionated by density gradient ultracentrifugation. Fractions of different densities were isolated and analyzed by SDS-PAGE followed either by staining with Coomassie Brilliant Blue stain or by Western blotting using anti-apoE antibodies. It was found that both the full-length apoE4, and the apoE4-mut1 and apoE4-mut2 mutants, associate with lipoproteins that float in the HDL region and to a lesser extent with particles in the LDL, IDL, and VLDL regions. Remarkably however, overexpression of both WT apoE4 and apoE4-mut2 resulted in displacement of apoA-I from HDL, whereas the overexpression of apoE4-mut1 does not displace apoA-I from the HDL density region (Fig. 7). We estimated, based on the SDS-PAGE analysis, that the apoA-I levels of mice infected with the apoE4-mut1 appear to be similar to those of apoE–/– mice, and over 90% of apoA-I was found in the HDL following density gradient ultracentrifugation (Fig. 7, compare A with E).
|
|
|
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
-phosphatidylcholine vesicles. Further deletion of residues 230–299 or 203–299 and 166–299 eliminated completely the ability of apoE to solubilize multilamellar dimyristoyl-L--phosphatidylcholine vesicles (11). Thus it is possible that the carboxyl-terminal 260–299 amino acids of apoE may be involved in the initial association of apoE with phospholipid, a process that may be required for the formation of apoE-containing lipoproteins. Whether the association of apoE with phospholipids in vivo requires participation of ABCA1 remains to be established. Once apoE is lipoprotein-bound, it may be taken up by the LDL receptor. The apoE-LDL receptor interactions control plasma cholesterol levels and confer protection from atherosclerosis (2). The contribution of receptors other than the LDL receptor in the clearance of apoE-containing lipoprotein remnants was previously assessed by studies in apoE–/– x LDLr–/– double-deficient mice (15). These studies have shown that neither the full-length apoE2 or apoE4 nor the truncated apoE2–202 or apoE4–202 corrected the high cholesterol profiles of the apoE–/– x LDLr–/– double-deficient mice (15). These data and other observations with full-length apoE2 suggest strongly that apoE-mediated lipoprotein clearance in mice is carried out mainly by the LDL receptor (15). In the absence of this receptor, lipoprotein receptor-related protein, other apoE recognizing lipoprotein receptors, and heparan sulfate proteoglycans (22, 23) are not sufficient to clear the lipoprotein remnants, which accumulate in the plasma of the double-deficient mice (15). In addition to the role of apoE in cholesterol homeostasis in circulation, plasma apoE levels correlate with plasma triglyceride levels in humans (24).
Hypertriglyceridemia is also induced in mice by overexpression of human apoE (12–15, 25). However, our recent studies have shown that hypertriglyceridemia did not occur when mice were infected with adenoviruses expressing truncated apoE forms lacking the 260–299 carboxyl-terminal domain (12–16). This set of experiments also showed that when the truncated apoE forms were co-expressed with the full-length apoE forms, they had a dominant effect and normalized the cholesterol levels of the apoE–/– mice (15).
These findings suggested that when full-length apoE is bound to triglyceride-rich VLDL particles, its receptor binding domain may be masked, thus preventing the direct apoE-mediated clearance of the VLDL particles prior to lipolysis. In contrast, when truncated apoE is bound to triglyceride-rich VLDL particles, its receptor binding domain may be exposed and may allow direct clearance of the VLDL particle (15).
The current study was designed to map the residues in the carboxyl-terminal region of apoE, which are responsible for hypertriglyceridemia. The rationale was that identification of these residues may lead to the generation of a recombinant apoE form with improved biological functions. We have focused on two regions of apoE between residues 260 and 299, which contain hydrophobic amino acids. The first region includes amino acids Leu-261, Trp-264, Phe-265, Leu-268, and Val-269, and the second region includes amino acids Trp-276, Leu-279, Val-280, and Val-283. A BLAST search of NCBI data base (www.ncbi.erlm.NIH.gov) showed that both regions are highly conserved among mammalian species. An in vivo adenovirus-mediated gene transfer of the two apoE mutants established unequivocally that the hydrophobic residues of apoE between amino acids 261–269 can account to a large extent for the induction of hypertriglyceridemia. Hypertriglyceridemia did not occur in mice infected with an adenovirus expressing apoE4-mut1 where these residues were changed into alanines. In contrast, infection of mice with an adenovirus expressing apoE4-mut2, where the hydrophobic residues between amino acids 276 and 283 were substituted by alanines, resulted in milder hypertriglyceridemia as compared with mice infected with the apoE4-expressing adenovirus.
It appears that the hydrophobic residues within the 261–269 as well as the 276–283 regions, affect the secretion of VLDL triglycerides. Mutations of these residues into alanines reduced the rate of hepatic VLDL triglyceride secretion to 27% of that caused by wild-type apoE4.
Our data also showed that an increase in the levels of the plasma lipoprotein lipase by co-infection with recombinant adenoviruses expressing the human lipoprotein lipase corrected the apoE-induced dyslipidemia in apoE–/– mice that overexpress full-length apoE4. This finding suggests that under the condition of apoE overexpression the activity of lipoprotein lipase becomes rate-limiting for the clearance of the hypertriglyceridemic VLDL. Substantial but less severe hypertriglyceridemia is also observed by the overexpression of apoE4-mut2, which is also corrected by co-infection with the lipoprotein lipase-expressing adenovirus. The difference in the severity of the hypertriglyceridemia between WT apoE4 and apoE4-mut2 may be related to the increased VLDL triglyceride secretion caused by the WT apoE4.
An important clue on the nature of the hypertriglyceridemic lipoprotein particles that accumulate in the plasma of the mice is provided by the clearance of apoE in mice co-infected with wild-type or mutant forms of apoE- and LpL-expressing adenoviruses. ApoE was cleared in mice treated with apoE4 and LpL, partially cleared in mice treated with apoE4-mut2 and LpL, and was unaffected in mice treated with apoE4-mut1 and LpL. The average apoE levels with or without treatment with lipoprotein lipase 2–6 days postinfection changed from 125 mg/dl to 10 mg/dl for apoE4, 150 mg/dl to 40 mg/dl for apoE4-mut2, and remained the same (170 mg/dl) for apoE4-mut1. The findings indicate that wild-type apoE4 resides on triglyceride-rich lipoprotein particles and following the hydrolysis of the triglycerides of these particles by LpL, apoE4 is recognized and cleared as a component of the remnant particles by the LDL-receptor. It appears that the majority of the mutant apoE4-mut1 may reside in another population of triglyceride-poor particles that are not cleared by the LDL receptor. Finally, the apoE4-mut2 may be partitioned in triglyceride-rich particles that are processed by LpL and cleared by the LDL receptor and triglyceride-poor particles that are not cleared by the LDL receptor. It is possible that the mutations introduced in apoE4-mut1 and to a lesser extent in apoE4-mut2 may have promoted the formation of triglyceride-poor apoE-containing lipoprotein particles that accumulate in the HDL region of these mice.
A very significant finding of this study is that apoE4 and apoE4-mut2 (W276A, L279A, V280A, and V283A) displaced apoA-I from HDL and promoted the formation of discoidal HDL. In contrast, apoE-mut1 (L261A, W264A, F265A, L268A, and V269A) did not displace apoA-I from the HDL region and did not affect the formation of spherical HDL particles. The findings suggest that when WT apoE4 or apoE4-mut2 is overexpressed, they may influence the formation or the stability of HDL. The effect of the apoE mutations on the biosynthesis and catabolism of VLDL and HDL is summarized in Fig. 9, A–C.
At the present time, it is not clear whether apoE overexpression interferes with the biogenesis of HDL through a pathway that involves the ABCA1 transporter or whether it affects its stability by displacing apoA-I from the surface of HDL. Both processes are expected to reduce the levels of HDL. The undesirable property of WT apoE to reduce plasma HDL levels can be overcome in the recombinant apoE4-mut1, were the hydrophobic residues in the 261–269 region were mutated into alanines.
The ability of recombinant apoE forms such as apoE4-mut1 to clear cholesterol without inducing hypertriglyceridemia or interfering with the formation of spherical HDL, makes them attractive therapeutic agents to correct remnant removal disorders. Therapeutic forms of apoE may involve pure recombinant protein associated with liposomes and potential gene therapy in the future.
|
FOOTNOTES |
|---|
To whom correspondence should be addressed: Section of Molecular Genetics, Whitaker Cardiovascular Institute, Dept. of Medicine, Boston University School of Medicine, 700 Albany St., W-509, Boston, Massachusetts, 02118. Tel.: 617-638-5085; Fax: 617-638-5141; E-mail: vzannis{at}bu.edu.
1 The abbreviations used are: ApoE, apolipoprotein E; apoA-I, apolipoprotein A-I; Ad, adenovirus; ELISA, enzyme-linked immunosorbent assay; FPLC, fast pressure liquid chromatography; GFP, green fluorescence protein; HDL, high density lipoprotein; VLDL, very low density lipoprotein; LpL, lipoprotein lipase; pfu, plaque-forming unit; WT, wild type; IDL, intermediate density lipoprotein; apoE–/–, apoE-deficient; LDLr–/–, LDL receptor-deficient.
2 K. E. Kypreos and V. I. Zannis, unpublished observations.
|
ACKNOWLEDGMENTS |
|---|
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Drosatos, D. Sanoudou, K. E. Kypreos, D. Kardassis, and V. I. Zannis A Dominant Negative Form of the Transcription Factor c-Jun Affects Genes That Have Opposing Effects on Lipid Homeostasis in Mice J. Biol. Chem., July 6, 2007; 282(27): 19556 - 19564. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Kypreos and V. I. Zannis LDL receptor deficiency or apoE mutations prevent remnant clearance and induce hypertriglyceridemia in mice J. Lipid Res., March 1, 2006; 47(3): 521 - 529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Lane and M. R. Farlow Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease J. Lipid Res., May 1, 2005; 46(5): 949 - 968. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |
